Mirum Pharmaceuticals, Inc. director Saira Ramasastry reported stock transactions, reflecting ongoing activity in the pharmaceutical preparations sector.
| Name | Mirum Pharmaceuticals, Inc. |
|---|---|
| CIK | 0001759425 |
| Tickers | MIRM |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Large accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 831281555 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 650-667-4085 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Mirum Pharmaceuticals, Inc. director Saira Ramasastry reported stock transactions, reflecting ongoing activity in the pharmaceutical preparations sector.
Mirum Pharmaceuticals, Inc. disclosed significant stock transactions by director Laura Brege, indicating potential shifts in ownership strategy.
Director Laura Brege of Mirum Pharmaceuticals sold 14,167 shares valued at $1.33 million, following a stock option exercise, according to SEC filing.
Mirum Pharmaceuticals announces successful Phase 3 study results for brelovitug, a treatment for chronic hepatitis delta virus, marking a significant milestone.
Mirum Pharmaceuticals CEO Christopher Peetz reports stock transactions, including acquisitions and dispositions, impacting investor confidence and corporate governance.
Mirum Pharmaceuticals discloses stock sale by former officer Joanne Quan, valued over $1.4 million, highlighting trends in the pharmaceutical sector.
Christopher Peetz of Mirum Pharmaceuticals plans to sell 20,000 shares as part of stock option exercises, reflecting ongoing liquidity management.
Mirum Pharmaceuticals reports strong Q3 2026 results, raising sales guidance and highlighting FDA approvals, signaling growth in the pharmaceutical sector.
Mirum Pharmaceuticals shares positive results from the PROGRESS study for ATEBRIOZ in pediatric patients with fibrodysplasia ossificans progressiva.
Mirum Pharmaceuticals reveals successful Phase 3 EXPAND study results for LIVMARLI, indicating significant efficacy in treating cholestatic liver diseases.
Christopher Peetz, CEO of Mirum Pharmaceuticals, acquires over 12,000 shares, signaling strong confidence in the company's future.
681 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-011400 | 001-38981 | 261579779 | 33 | 6340 | |||
| 2026-11-17 | 4 | xslF345X06/form4-11172026_101145.xml | 0001547959-26-000019 | 8548 | ||||||
| 2026-11-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-011118 | 001-38981 | 261560405 | 33 | 4750 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001274173-26-000242 | 005-91075 | 261558213 | 34 | 13073 | |||
| 2026-11-13 | 4 | xslF345X06/form4-11132026_091146.xml | 0001365619-26-000007 | 10643 | ||||||
| 2026-11-12 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-011005 | 001-38981 | 261543651 | 33 | 4939 | |||
| 2026-11-10 | 8-K | 8-K | 8.01 | 0001759425-26-000064 | 001-38981 | 261537991 | 34 | 171797 | 1 | 1 |
| 2026-11-04 | 4 | xslF345X06/form4-11052026_011100.xml | 0001614740-26-000015 | 9358 | ||||||
| 2026-11-04 | 144 | xsl144X01/primary_doc.xml | 0001670138-26-000007 | 001-38981 | 261524309 | 33 | 4724 | |||
| 2026-11-04 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-010687 | 001-38981 | 261522782 | 33 | 6339 | |||
| 2026-11-03 | 10-Q | 10-Q | 0001759425-26-000062 | 001-38981 | 261517371 | 34 | 10320109 | 1 | 1 | |
| 2026-11-03 | 8-K | 8-K | 2.02,9.01 | 0001759425-26-000061 | 001-38981 | 261517260 | 34 | 1607179 | 1 | 1 |
| 2026-10-26 | 8-K | 8-K | 8.01 | 0001759425-26-000054 | 001-38981 | 261486459 | 34 | 157840 | 1 | 1 |
| 2026-10-19 | 4 | xslF345X06/form4-10192026_041001.xml | 0001974200-26-000014 | 6985 | ||||||
| 2026-10-14 | 4 | xslF345X06/form4-10142026_081046.xml | 0002155916-26-000004 | 8300 | ||||||
| 2026-10-13 | 8-K | 8-K | 8.01 | 0001759425-26-000051 | 001-38981 | 261454742 | 34 | 181767 | 1 | 1 |
| 2026-10-06 | 4 | xslF345X06/form4-10072026_121019.xml | 0001614740-26-000014 | 11298 | ||||||
| 2026-09-28 | 8-K | 8-K | 8.01 | 0001759425-26-000049 | 001-38981 | 261412012 | 34 | 194669 | 1 | 1 |
| 2026-09-22 | 3 | xslF345X06/form3-09232026_010947.xml | 0002155916-26-000003 | 9728 | ||||||
| 2026-09-15 | 144 | xsl144X01/primary_doc.xml | 0001197350-26-000011 | 001-38981 | 261381021 | 33 | 6095 | |||
| 2026-09-15 | 4 | xslF345X06/form4-09152026_040901.xml | 0001197350-26-000010 | 8868 | ||||||
| 2026-09-08 | 8-K | 8-K | 5.02 | 0001759425-26-000047 | 001-38981 | 261363493 | 34 | 143760 | 1 | 1 |
| 2026-09-03 | 4 | xslF345X06/form4-09032026_100913.xml | 0001974200-26-000013 | 4964 | ||||||
| 2026-09-03 | 4 | xslF345X06/form4-09032026_100954.xml | 0001614740-26-000013 | 11868 | ||||||
| 2026-09-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008986 | 001-38981 | 261354769 | 33 | 7690 | |||
| 2026-09-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008900 | 001-38981 | 261351007 | 33 | 6339 | |||
| 2026-08-19 | 4 | xslF345X06/form4-08192026_100826.xml | 0001974200-26-000012 | 8450 | ||||||
| 2026-08-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-008352 | 001-38981 | 261292053 | 33 | 6874 | |||
| 2026-08-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001274173-26-000210 | 005-91075 | 261271760 | 34 | 13037 | |||
| 2026-08-12 | 4 | xslF345X06/form4-08122026_090835.xml | 0001197350-26-000009 | 5533 | ||||||
| 2026-08-11 | 4 | xslF345X06/form4-08112026_090838.xml | 0001614740-26-000012 | 13539 | ||||||
| 2026-08-11 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007935 | 001-38981 | 261263316 | 33 | 6678 | |||
| 2026-08-10 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007862 | 001-38981 | 261258674 | 33 | 6339 | |||
| 2026-08-06 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000315066-26-002080 | 005-91075 | 261247157 | 34 | 11545 | |||
| 2026-08-05 | 4 | xslF345X06/form4-08052026_080847.xml | 0001974200-26-000011 | 4970 | ||||||
| 2026-08-05 | 10-Q | 10-Q | 0001759425-26-000045 | 001-38981 | 261243430 | 34 | 9786362 | 1 | 1 | |
| 2026-08-05 | 8-K | 8-K | 2.02,9.01 | 0001759425-26-000044 | 001-38981 | 261243245 | 34 | 1595210 | 1 | 1 |
| 2026-08-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-007486 | 001-38981 | 261232891 | 33 | 6840 | |||
| 2026-07-08 | 4 | xslF345X06/form4-07082026_090744.xml | 0001614740-26-000011 | 15446 | ||||||
| 2026-07-08 | 4 | xslF345X06/form4-07082026_090727.xml | 0001197350-26-000008 | 10610 | ||||||
| 2026-07-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006855 | 001-38981 | 261155972 | 33 | 5619 | |||
| 2026-07-06 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006854 | 001-38981 | 261155959 | 33 | 5471 | |||
| 2026-07-02 | 4 | xslF345X06/form4-07022026_100751.xml | 0001974200-26-000010 | 4967 | ||||||
| 2026-07-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006797 | 001-38981 | 261146619 | 33 | 5536 | |||
| 2026-06-18 | 4 | xslF345X06/form4-06182026_100638.xml | 0001974200-26-000009 | 4968 | ||||||
| 2026-06-18 | 8-K | 8-K | 5.07 | 0001193125-26-275811 | 001-38981 | 261102515 | 34 | 150003 | 1 | 1 |
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080620.xml | 0001349376-26-000004 | 15067 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080618.xml | 0001854337-26-000004 | 15108 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080616.xml | 0001547959-26-000016 | 15071 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080609.xml | 0001727275-26-000004 | 15374 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080608.xml | 0001365619-26-000005 | 15303 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080605.xml | 0001365617-26-000004 | 15281 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080603.xml | 0001379344-26-000005 | 8245 | ||||||
| 2026-06-17 | 4 | xslF345X06/form4-06172026_080601.xml | 0001240122-26-000005 | 15094 | ||||||
| 2026-06-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-006244 | 001-38981 | 261098239 | 33 | 5991 | |||
| 2026-06-09 | 4 | xslF345X06/form4-06102026_010600.xml | 0001197350-26-000007 | 12991 | ||||||
| 2026-06-08 | 4 | xslF345X06/form4-06082026_080628.xml | 0001650131-26-000011 | 6977 | ||||||
| 2026-06-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-005748 | 001-38981 | 261072914 | 33 | 5471 | |||
| 2026-06-02 | 4 | xslF345X06/form4-06022026_070609.xml | 0001614740-26-000010 | 19217 | ||||||
| 2026-06-02 | 4 | xslF345X06/form4-06022026_070607.xml | 0001349376-26-000002 | 7177 | ||||||
| 2026-06-02 | 4 | xslF345X06/form4-06022026_070605.xml | 0001854337-26-000002 | 7227 | ||||||
| 2026-06-02 | 4 | xslF345X06/form4-06022026_070603.xml | 0001547959-26-000011 | 8828 | ||||||
| 2026-06-02 | 4 | xslF345X06/form4-06022026_070601.xml | 0001379344-26-000003 | 7222 | ||||||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-005448 | 001-38981 | 261052534 | 33 | 5619 | |||
| 2026-06-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-005336 | 001-38981 | 261050633 | 33 | 6906 | |||
| 2026-05-18 | 4 | xslF345X06/form4-05192026_120532.xml | 0001547959-26-000009 | 8547 | ||||||
| 2026-05-18 | 8-K | 8-K | 1.01,2.03,3.02,8.01,9.01 | 0001193125-26-228902 | 001-38981 | 26993156 | 34 | 997439 | 1 | 1 |
| 2026-05-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-004580 | 001-38981 | 26987246 | 33 | 6183 | |||
| 2026-05-06 | 10-Q | 10-Q | 0001759425-26-000037 | 001-38981 | 26948345 | 34 | 8675652 | 1 | 1 | |
| 2026-05-06 | 8-K | 8-K | 2.02,9.01 | 0001759425-26-000036 | 001-38981 | 26948226 | 34 | 1578553 | 1 | 1 |
| 2026-05-04 | 8-K | 8-K | 8.01 | 0001193125-26-202609 | 001-38981 | 26934680 | 34 | 166661 | 1 | 1 |
| 2026-04-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0002012383-26-001752 | 005-91075 | 26901121 | 34 | 11169 | |||
| 2026-04-27 | 8-K | 8-K | 8.01 | 0001193125-26-179048 | 001-38981 | 26896639 | 34 | 167556 | 1 | 1 |
| 2026-04-24 | ARS | ARS | 0001140361-26-016603 | 001-38981 | 26890934 | 34 | 1121814 | |||
| 2026-04-23 | DEFA14A | DEFA14A | 0001759425-26-000028 | 001-38981 | 26889290 | 34 | 522030 | |||
| 2026-04-23 | DEF 14A | DEF 14A | 0001759425-26-000027 | 001-38981 | 26889246 | 34 | 13236129 | 1 | 1 | |
| 2026-04-16 | 4 | xslF345X06/form4-04172026_120419.xml | 0001547959-26-000007 | 8548 | ||||||
| 2026-04-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-003474 | 001-38981 | 26864268 | 33 | 6183 | |||
| 2026-04-08 | 8-K/A | 8-K/A | 9.01 | 0001759425-26-000021 | 001-38981 | 26848275 | 34 | 831499 | 1 | 1 |
| 2026-03-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-001893 | 005-91075 | 26802469 | 34 | 7174 | |||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070311.xml | 0001197350-26-000006 | 14439 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070309.xml | 0001670138-26-000005 | 14487 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070313.xml | 0001547959-26-000006 | 8412 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070307.xml | 0001650131-26-000010 | 18238 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070304.xml | 0001974200-26-000008 | 18221 | ||||||
| 2026-03-17 | 4 | xslF345X05/form4-03172026_070301.xml | 0001614740-26-000009 | 18964 | ||||||
| 2026-03-17 | 144 | xsl144X01/primary_doc.xml | 0001197350-26-000005 | 001-38981 | 26764150 | 33 | 12011 | |||
| 2026-03-17 | 144 | xsl144X01/primary_doc.xml | 0001670138-26-000004 | 001-38981 | 26764139 | 33 | 12049 | |||
| 2026-03-17 | 144 | xsl144X01/primary_doc.xml | 0001650131-26-000009 | 001-38981 | 26764126 | 33 | 12934 | |||
| 2026-03-17 | 144 | xsl144X01/primary_doc.xml | 0001974200-26-000007 | 001-38981 | 26764106 | 33 | 12904 | |||
| 2026-03-17 | 144 | xsl144X01/primary_doc.xml | 0001614740-26-000008 | 001-38981 | 26764094 | 33 | 13049 | |||
| 2026-03-16 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-002614 | 001-38981 | 26756632 | 33 | 7617 | |||
| 2026-03-11 | 4 | xslF345X05/form4-03112026_080315.xml | 0001650131-26-000008 | 6836 | ||||||
| 2026-02-25 | S-3ASR | S-3ASR | 0001193125-26-072098 | 333-293762 | 26680166 | 33 | 542787 | 1 | 1 | |
| 2026-02-25 | S-8 | S-8 | 0001759425-26-000015 | 333-293748 | 26679338 | 33 | 236638 | 1 | 1 | |
| 2026-02-25 | 10-K | 10-K | 0001759425-26-000013 | 001-38981 | 26679118 | 34 | 11405133 | 1 | 1 | |
| 2026-02-25 | 8-K | 8-K | 2.02,9.01 | 0001759425-26-000010 | 001-38981 | 26678377 | 34 | 1589539 | 1 | 1 |
| 2026-02-17 | 4 | xslF345X05/form4-02172026_090212.xml | 0001547959-26-000005 | 8413 | ||||||
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-26-000084 | 005-91075 | 26642368 | 34 | 12076 | |||
| 2026-02-13 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-001236 | 001-38981 | 26632523 | 33 | 6900 | |||
| 2026-02-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-26-001063 | 005-91075 | 26630815 | 34 | 11728 | |||
| 2026-02-03 | 4 | xslF345X05/form4-02032026_090206.xml | 0001650131-26-000007 | 4826 | ||||||
| 2026-02-03 | 4 | xslF345X05/form4-02032026_090204.xml | 0001614740-26-000007 | 5541 | ||||||
| 2026-02-03 | 4 | xslF345X05/form4-02032026_090202.xml | 0001974200-26-000006 | 8891 | ||||||
| 2026-02-02 | 144 | xsl144X01/primary_doc.xml | 0001974200-26-000005 | 001-38981 | 26589835 | 33 | 6289 | |||
| 2026-02-02 | 144 | xsl144X01/primary_doc.xml | 0001650131-26-000006 | 001-38981 | 26589822 | 33 | 6306 | |||
| 2026-02-02 | 144 | xsl144X01/primary_doc.xml | 0001614740-26-000006 | 001-38981 | 26589809 | 33 | 6415 | |||
| 2026-01-30 | 4 | xslF345X05/form4-01302026_060108.xml | 0001974200-26-000004 | 10673 | ||||||
| 2026-01-30 | 4 | xslF345X05/form4-01302026_060106.xml | 0001670138-26-000003 | 10680 | ||||||
| 2026-01-30 | 4 | xslF345X05/form4-01302026_060105.xml | 0001197350-26-000004 | 10626 | ||||||
| 2026-01-30 | 4 | xslF345X05/form4-01302026_060103.xml | 0001650131-26-000005 | 10682 | ||||||
| 2026-01-30 | 4 | xslF345X05/form4-01302026_060101.xml | 0001614740-26-000005 | 10693 | ||||||
| 2026-01-29 | D | xslFormDX01/primary_doc.xml | 06c | 0001759425-26-000005 | 021-571698 | 26578053 | 33 | 14492 | ||
| 2026-01-28 | 144 | xsl144X01/primary_doc.xml | 0001974200-26-000003 | 001-38981 | 26574028 | 33 | 5527 | |||
| 2026-01-28 | 144 | xsl144X01/primary_doc.xml | 0001197350-26-000003 | 001-38981 | 26574023 | 33 | 5479 | |||
| 2026-01-28 | 144 | xsl144X01/primary_doc.xml | 0001650131-26-000004 | 001-38981 | 26574021 | 33 | 5541 | |||
| 2026-01-28 | 144 | xsl144X01/primary_doc.xml | 0001614740-26-000004 | 001-38981 | 26574016 | 33 | 5647 | |||
| 2026-01-27 | 4 | xslF345X05/form4-01272026_040108.xml | 0001197350-26-000002 | 8882 | ||||||
| 2026-01-27 | 4 | xslF345X05/form4-01272026_040106.xml | 0001650131-26-000003 | 8896 | ||||||
| 2026-01-27 | 4 | xslF345X05/form4-01272026_040105.xml | 0001974200-26-000002 | 8893 | ||||||
| 2026-01-27 | 4 | xslF345X05/form4-01272026_040103.xml | 0001614740-26-000003 | 9571 | ||||||
| 2026-01-27 | 4 | xslF345X05/form4-01272026_090122.xml | 0001365617-26-000002 | 8845 | ||||||
| 2026-01-27 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001231919-26-000093 | 005-91075 | 26565646 | 34 | 93593 | |||
| 2026-01-26 | 8-K | 8-K | 2.01,7.01,8.01,9.01 | 0001193125-26-022582 | 001-38981 | 26560602 | 34 | 175459 | 1 | 1 |
| 2026-01-23 | 4 | xslF345X05/form4-01232026_050110.xml | 0001974200-26-000001 | 8894 | ||||||
| 2026-01-23 | 4 | xslF345X05/form4-01232026_050108.xml | 0001670138-26-000002 | 8937 | ||||||
| 2026-01-23 | 4 | xslF345X05/form4-01232026_050106.xml | 0001197350-26-000001 | 9118 | ||||||
| 2026-01-23 | 4 | xslF345X05/form4-01232026_050104.xml | 0001650131-26-000002 | 9132 | ||||||
| 2026-01-23 | 4 | xslF345X05/form4-01232026_050101.xml | 0001614740-26-000002 | 9572 | ||||||
| 2026-01-21 | 4 | xslF345X05/form4-01212026_040103.xml | 0001670138-26-000001 | 9088 | ||||||
| 2026-01-16 | 4 | xslF345X05/form4-01162026_090102.xml | 0001547959-26-000002 | 8412 | ||||||
| 2026-01-15 | 144 | xsl144X01/primary_doc.xml | 0001950047-26-000431 | 001-38981 | 26536236 | 33 | 6183 | |||
| 2026-01-12 | 8-K | 8-K | 2.02,7.01,9.01 | 0001759425-26-000004 | 001-38981 | 26524848 | 34 | 9117375 | 1 | 1 |
| 2026-01-02 | 4 | xslF345X05/form4-01022026_090131.xml | 0001614740-26-000001 | 5536 | ||||||
| 2025-12-23 | 4 | xslF345X05/form4-12232025_111209.xml | 0001547959-25-000008 | 8408 | ||||||
| 2025-12-23 | 4 | xslF345X05/form4-12232025_111200.xml | 0001240122-25-000011 | 9892 | ||||||
| 2025-12-22 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010594 | 001-38981 | 251592417 | 33 | 5467 | |||
| 2025-12-19 | 4 | xslF345X05/form4-12192025_091243.xml | 0001547959-25-000007 | 9917 | ||||||
| 2025-12-19 | 8-K | 8-K | 8.01 | 0001193125-25-326822 | 001-38981 | 251587563 | 34 | 137260 | 1 | 1 |
| 2025-12-19 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010541 | 001-38981 | 251587541 | 33 | 6224 | |||
| 2025-12-19 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-25-325825 | 001-38981 | 251585136 | 34 | 488009 | 1 | 1 |
| 2025-12-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-010493 | 001-38981 | 251583165 | 33 | 4750 | |||
| 2025-12-08 | 8-K | 8-K | 1.01,3.02,7.01,8.01,9.01 | 0001193125-25-310611 | 001-38981 | 251554680 | 34 | 5724231 | 1 | 1 |
| 2025-12-05 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000321 | 005-91075 | 251552108 | 34 | 9573 | |||
| 2025-12-02 | 4 | xslF345X05/form4-12022025_091224.xml | 0001240122-25-000007 | 9895 | ||||||
| 2025-12-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009503 | 001-38981 | 251539686 | 33 | 5509 | |||
| 2025-11-25 | 4 | xslF345X05/form4-11252025_041104.xml | 0001240122-25-000006 | 9895 | ||||||
| 2025-11-21 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-009188 | 001-38981 | 251508021 | 33 | 4794 | |||
| 2025-11-20 | 4 | xslF345X05/form4-11202025_091110.xml | 0001614740-25-000005 | 7800 | ||||||
| 2025-11-17 | 8-K | 8-K | 8.01 | 0001759425-25-000057 | 001-38981 | 251491656 | 34 | 143262 | 1 | 1 |
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000921895-25-003107 | 005-91075 | 251486366 | 34 | 23208 | |||
| 2025-11-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000293 | 005-91075 | 251483223 | 34 | 9572 | |||
| 2025-11-04 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001231919-25-000420 | 005-91075 | 251450855 | 34 | 46203 | |||
| 2025-11-04 | 10-Q | 10-Q | 0001759425-25-000054 | 001-38981 | 251448904 | 34 | 8320793 | 1 | 1 | |
| 2025-11-04 | 8-K | 8-K | 2.02,9.01 | 0001759425-25-000053 | 001-38981 | 251448827 | 34 | 1584238 | 1 | 1 |
| 2025-09-12 | 4 | xslF345X05/form4-09122025_080904.xml | 0001415889-25-024463 | 10500 | ||||||
| 2025-09-12 | 4 | xslF345X05/form4-09122025_080902.xml | 0001415889-25-024462 | 8735 | ||||||
| 2025-09-11 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006973 | 001-38981 | 251308533 | 33 | 4695 | |||
| 2025-09-10 | 4 | xslF345X05/form4-09102025_090933.xml | 0001415889-25-024128 | 8575 | ||||||
| 2025-09-09 | S-8 | S-8 | 0001759425-25-000045 | 333-290137 | 251303825 | 33 | 402163 | 1 | 1 | |
| 2025-09-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-006827 | 001-38981 | 251300094 | 33 | 4657 | |||
| 2025-08-20 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0001415889-25-022494 | 005-91075 | 251237744 | 34 | 38131 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000218 | 005-91075 | 251215752 | 34 | 9573 | |||
| 2025-08-12 | 4 | xslF345X05/form4-08122025_110857.xml | 0001415889-25-021522 | 9063 | ||||||
| 2025-08-12 | 4 | xslF345X05/form4-08122025_110854.xml | 0001415889-25-021521 | 9224 | ||||||
| 2025-08-12 | S-3ASR | S-3ASR | 0001193125-25-178937 | 333-289525 | 251206639 | 33 | 1437496 | 1 | 1 | |
| 2025-08-11 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005599 | 001-38981 | 251202009 | 33 | 5705 | |||
| 2025-08-08 | 4 | xslF345X05/form4-08082025_080836.xml | 0001415889-25-021351 | 8498 | ||||||
| 2025-08-08 | 4 | xslF345X05/form4-08082025_080828.xml | 0001415889-25-021350 | 9617 | ||||||
| 2025-08-07 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005530 | 001-38981 | 251194540 | 33 | 6372 | |||
| 2025-08-07 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-005528 | 001-38981 | 251194520 | 33 | 4939 | |||
| 2025-08-06 | 10-Q | 10-Q | 0001759425-25-000041 | 001-38981 | 251189518 | 34 | 7887334 | 1 | 1 | |
| 2025-08-06 | 8-K | 8-K | 2.02,9.01 | 0001759425-25-000040 | 001-38981 | 251189420 | 34 | 270199 | 1 | 1 |
| 2025-07-03 | 4 | xslF345X05/form4-07032025_100743.xml | 0001415889-25-019378 | 10396 | ||||||
| 2025-07-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004832 | 001-38981 | 251104723 | 33 | 5609 | |||
| 2025-06-13 | 4 | xslF345X05/form4-06132025_080649.xml | 0001415889-25-017188 | 4596 | ||||||
| 2025-06-11 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-004131 | 001-38981 | 251039937 | 33 | 4739 | |||
| 2025-06-06 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000183 | 005-91075 | 251029573 | 34 | 9573 | |||
| 2025-06-04 | 4 | xslF345X05/form4-06042025_080640.xml | 0001415889-25-015570 | 9619 | ||||||
| 2025-06-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-003778 | 001-38981 | 251020683 | 33 | 5459 | |||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110625.xml | 0001415889-25-015306 | 11836 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110622.xml | 0001415889-25-015305 | 14441 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110615.xml | 0001415889-25-015304 | 8102 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110641.xml | 0001415889-25-015303 | 12092 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110622.xml | 0001415889-25-015302 | 12089 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110626.xml | 0001415889-25-015301 | 11886 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110600.xml | 0001415889-25-015300 | 7890 | ||||||
| 2025-06-02 | 4 | xslF345X05/form4-06022025_110638.xml | 0001415889-25-015299 | 11842 | ||||||
| 2025-06-02 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-003721 | 001-38981 | 251016576 | 33 | 4699 | |||
| 2025-05-30 | 8-K | 8-K | 5.07 | 0001759425-25-000034 | 001-38981 | 251011595 | 34 | 152304 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000178 | 005-91075 | 25951989 | 34 | 9570 | |||
| 2025-05-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000128 | 005-91075 | 25943806 | 34 | 10671 | |||
| 2025-05-07 | 10-Q | 10-Q | 0001759425-25-000032 | 001-38981 | 25921374 | 34 | 7353653 | 1 | 1 | |
| 2025-05-07 | 8-K | 8-K | 2.02,9.01 | 0001759425-25-000030 | 001-38981 | 25921132 | 34 | 262359 | 1 | 1 |
| 2025-05-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000112 | 005-91075 | 25919905 | 34 | 9571 | |||
| 2025-04-14 | ARS | ARS | 0001140361-25-013762 | 001-38981 | 25836219 | 34 | 1121633 | |||
| 2025-04-14 | DEFA14A | DEFA14A | 0001759425-25-000024 | 001-38981 | 25836099 | 34 | 274008 | |||
| 2025-04-14 | DEF 14A | DEF 14A | 0001759425-25-000022 | 001-38981 | 25836077 | 34 | 10014745 | 1 | 1 | |
| 2025-03-19 | 4 | xslF345X05/form4-03192025_090306.xml | 0001415889-25-008608 | 5226 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_090306.xml | 0001415889-25-008558 | 18261 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_090304.xml | 0001415889-25-008557 | 8765 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_090301.xml | 0001415889-25-008556 | 9473 | ||||||
| 2025-03-18 | 4 | xslF345X05/form4-03182025_090327.xml | 0001415889-25-008439 | 8616 | ||||||
| 2025-03-18 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-001997 | 001-38981 | 25748427 | 33 | 10968 | |||
| 2025-03-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-001926 | 001-38981 | 25744780 | 33 | 8904 | |||
| 2025-03-12 | 4 | xslF345X05/form4-03122025_080317.xml | 0001415889-25-007828 | 10407 | ||||||
| 2025-03-10 | 4 | xslF345X05/form4-03102025_090354.xml | 0001415889-25-007540 | 8616 | ||||||
| 2025-03-06 | 4 | xslF345X05/form4-03062025_100339.xml | 0001415889-25-007260 | 10164 | ||||||
| 2025-03-05 | 4 | xslF345X05/form4-03052025_090314.xml | 0001415889-25-006955 | 6521 | ||||||
| 2025-03-04 | 144 | xsl144X01/primary_doc.xml | 0001972362-25-000219 | 001-38981 | 25705518 | 33 | 9336 | |||
| 2025-03-04 | 4 | xslF345X05/form4-03042025_090312.xml | 0001415889-25-006524 | 11516 | ||||||
| 2025-03-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-25-001456 | 001-38981 | 25698859 | 33 | 7237 | |||
| 2025-02-26 | S-8 | S-8 | 0001759425-25-000016 | 333-285272 | 25670321 | 33 | 248023 | 1 | 1 | |
| 2025-02-26 | 10-K | 10-K | 0001759425-25-000014 | 001-38981 | 25670079 | 34 | 11558856 | 1 | 1 | |
| 2025-02-26 | 8-K | 8-K | 2.02,9.01 | 0001759425-25-000012 | 001-38981 | 25669975 | 34 | 286215 | 1 | 1 |
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000068 | 005-91075 | 25625519 | 34 | 9582 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001274173-25-000062 | 005-91075 | 25625497 | 34 | 10751 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-001012 | 005-91075 | 25625464 | 34 | 14889 | |||
| 2025-02-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001580642-25-001010 | 005-91075 | 25625378 | 34 | 13869 | |||
| 2025-02-04 | 4 | xslF345X05/form4-02042025_050206.xml | 0001415889-25-002982 | 4840 | ||||||
| 2025-02-04 | 4 | xslF345X05/form4-02042025_050204.xml | 0001415889-25-002981 | 5545 | ||||||
| 2025-02-04 | 4 | xslF345X05/form4-02042025_050201.xml | 0001415889-25-002980 | 8893 | ||||||
| 2025-01-27 | 4 | xslF345X05/form4-01272025_090133.xml | 0001415889-25-002137 | 8913 | ||||||
| 2025-01-27 | 4 | xslF345X05/form4-01272025_090146.xml | 0001415889-25-002136 | 7195 | ||||||
| 2025-01-27 | 4 | xslF345X05/form4-01272025_090147.xml | 0001415889-25-002135 | 8887 | ||||||
| 2025-01-27 | 4 | xslF345X05/form4-01272025_090100.xml | 0001415889-25-002134 | 9577 | ||||||
| 2025-01-23 | 4 | xslF345X05/form4-01232025_100106.xml | 0001415889-25-001955 | 10679 | ||||||
| 2025-01-23 | 4 | xslF345X05/form4-01232025_100156.xml | 0001415889-25-001954 | 8100 | ||||||
| 2025-01-23 | 4 | xslF345X05/form4-01232025_100126.xml | 0001415889-25-001953 | 8097 | ||||||
| 2025-01-23 | 4 | xslF345X05/form4-01232025_100138.xml | 0001415889-25-001952 | 10701 | ||||||
| 2025-01-23 | 4 | xslF345X05/form4-01232025_100149.xml | 0001415889-25-001951 | 10687 | ||||||
| 2025-01-21 | 4 | xslF345X05/form4-01212025_090130.xml | 0001415889-25-001779 | 8807 | ||||||
| 2025-01-13 | 8-K | 8-K | 2.02,7.01,9.01 | 0001759425-25-000003 | 001-38981 | 25524977 | 34 | 6706659 | 1 | 1 |
| 2025-01-08 | 4 | xslF345X05/form4-01082025_090118.xml | 0001415889-25-001144 | 4840 | ||||||
| 2025-01-08 | 4 | xslF345X05/form4-01082025_090146.xml | 0001415889-25-001143 | 5545 | ||||||
| 2025-01-08 | 4 | xslF345X05/form4-01082025_090147.xml | 0001415889-25-001142 | 8832 | ||||||
| 2024-11-15 | 4 | xslF345X05/form4-11152024_101149.xml | 0001415889-24-026974 | 8501 | ||||||
| 2024-11-14 | SC 13G/A | AMENDMENT NO. 1 TO SCHEDULE 13G | 0000921895-24-002733 | 005-91075 | 241463473 | 34 | 276880 | |||
| 2024-11-14 | 4 | xslF345X05/form4-11142024_091104.xml | 0001415889-24-026873 | 4850 | ||||||
| 2024-11-14 | 4 | xslF345X05/form4-11142024_091128.xml | 0001415889-24-026870 | 4849 | ||||||
| 2024-11-14 | 4 | xslF345X05/form4-11142024_091113.xml | 0001415889-24-026868 | 5616 | ||||||
| 2024-11-14 | SC 13G/A | JANUS AMENDMENT | 0001274173-24-000125 | 005-91075 | 241459621 | 34 | 10525 | |||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001580642-24-006956 | 005-91075 | 241459364 | 34 | 56825 | |||
| 2024-11-12 | SC 13G/A | us6047491013_111224.txt | 0002012383-24-004377 | 005-91075 | 241445738 | 34 | 13906 | |||
| 2024-11-12 | 10-Q | 10-Q | 0001759425-24-000038 | 001-38981 | 241443634 | 34 | 7888048 | 1 | 1 | |
| 2024-11-12 | 8-K | 8-K | 2.02,9.01 | 0001759425-24-000037 | 001-38981 | 241443536 | 34 | 282705 | 1 | 1 |
| 2024-10-22 | SC 13G/A | us6047491013_102224.txt | 0002012383-24-001602 | 005-91075 | 241387327 | 34 | 13893 | |||
| 2024-10-01 | 4 | xslF345X05/form4-10012024_081000.xml | 0001415889-24-024195 | 5589 | ||||||
| 2024-09-20 | 4 | xslF345X05/form4-09202024_080957.xml | 0001415889-24-023777 | 6448 | ||||||
| 2024-09-12 | 4 | xslF345X05/form4-09122024_080946.xml | 0001415889-24-023289 | 7091 | ||||||
| 2024-09-10 | 4 | xslF345X05/form4-09102024_090910.xml | 0001415889-24-023154 | 6999 | ||||||
| 2024-08-07 | 10-Q | 10-Q | 0001759425-24-000031 | 001-38981 | 241183863 | 34 | 8111583 | 1 | 1 | |
| 2024-08-07 | 8-K | 8-K | 2.02,9.01 | 0001759425-24-000029 | 001-38981 | 241183611 | 34 | 281877 | 1 | 1 |
| 2024-07-24 | 4 | xslF345X05/form4-07242024_090744.xml | 0001415889-24-020053 | 7717 | ||||||
| 2024-07-10 | SC 13G | JANUS HENDERSON OWNS 10 | 0001274173-24-000073 | 005-91075 | 241109435 | 34 | 10526 | |||
| 2024-07-03 | 4 | xslF345X05/form4-07032024_100734.xml | 0001415889-24-019276 | 8743 | ||||||
| 2024-07-01 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-005183 | 001-38981 | 241092040 | 33 | 4857 | |||
| 2024-06-25 | 4 | xslF345X05/form4-06252024_090650.xml | 0001415889-24-018159 | 9174 | ||||||
| 2024-06-24 | 144 | xsl144X01/primary_doc.xml | 0001950047-24-004995 | 001-38981 | 241064810 | 33 | 4842 | |||
| 2024-06-17 | 8-K | 8-K | 8.01 | 0001193125-24-162056 | 001-38981 | 241046995 | 34 | 152248 | 1 | 1 |
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100632.xml | 0001415889-24-016071 | 8113 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100631.xml | 0001415889-24-016070 | 7857 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100643.xml | 0001415889-24-016069 | 7901 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100651.xml | 0001415889-24-016068 | 7890 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100603.xml | 0001415889-24-016066 | 7849 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100617.xml | 0001415889-24-016065 | 8118 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100615.xml | 0001415889-24-016064 | 12914 | ||||||
| 2024-06-07 | 4 | xslF345X05/form4-06072024_100607.xml | 0001415889-24-016063 | 7887 | ||||||
| 2024-06-06 | 8-K | 8-K | 5.07 | 0001759425-24-000023 | 001-38981 | 241026047 | 34 | 166009 | 1 | 1 |
| 2024-05-31 | 8-K | 8-K | 8.01 | 0001193125-24-151965 | 001-38981 | 241010851 | 34 | 151034 | 1 | 1 |
| 2024-05-16 | 4 | xslF345X05/form4-05162024_040533.xml | 0001415889-24-013356 | 4812 | ||||||
| 2024-05-16 | 4 | xslF345X05/form4-05162024_040530.xml | 0001415889-24-013355 | 5580 | ||||||
| 2024-05-16 | 4 | xslF345X05/form4-05162024_040526.xml | 0001415889-24-013354 | 5563 | ||||||
| 2024-05-08 | 10-Q | 10-Q | 0001759425-24-000019 | 001-38981 | 24926320 | 34 | 6973629 | 1 | 1 | |
| 2024-05-08 | 8-K | 8-K | 2.02,9.01 | 0001759425-24-000017 | 001-38981 | 24925796 | 34 | 255251 | 1 | 1 |
| 2024-04-23 | ARS | ARS | 0001140361-24-021367 | 001-38981 | 24865221 | 34 | 1753035 | |||
| 2024-04-23 | DEFA14A | DEFA14A | 0001759425-24-000012 | 001-38981 | 24865095 | 34 | 458936 | |||
| 2024-04-23 | DEF 14A | DEF 14A | 0001759425-24-000011 | 001-38981 | 24865085 | 34 | 1363831 | |||
| 2024-03-27 | 4 | xslF345X05/form4-03282024_120312.xml | 0001415889-24-009280 | 4558 | ||||||
| 2024-03-25 | 4 | xslF345X05/form4-03252024_090335.xml | 0001415889-24-009046 | 5011 | ||||||
| 2024-03-18 | 4 | xslF345X05/form4-03182024_090306.xml | 0001415889-24-008322 | 4807 | ||||||
| 2024-03-18 | 4 | xslF345X05/form4-03182024_090327.xml | 0001415889-24-008320 | 5496 | ||||||
| 2024-03-18 | 4 | xslF345X05/form4-03182024_090300.xml | 0001415889-24-008316 | 6661 | ||||||
| 2024-03-18 | 4 | xslF345X05/form4-03182024_090320.xml | 0001415889-24-008313 | 5836 | ||||||
| 2024-03-18 | 4 | xslF345X05/form4-03182024_090313.xml | 0001415889-24-008311 | 4558 | ||||||
| 2024-03-15 | S-8 | S-8 | 0001193125-24-069301 | 333-278011 | 24756164 | 33 | 81416 | |||
| 2024-03-15 | 10-K | 10-K | 0000950170-24-032289 | 001-38981 | 24755770 | 34 | 15921226 | 1 | 1 | |
| 2024-02-28 | NT 10-K | NT 10-K | 0001193125-24-050798 | 001-38981 | 24696573 | 34 | 26767 | |||
| 2024-02-28 | 8-K | 8-K | 2.02,9.01 | 0001759425-24-000005 | 001-38981 | 24695204 | 34 | 287700 | 1 | 1 |
| 2024-02-14 | SC 13G/A | SC 13G/A | 0001580642-24-000990 | 005-91075 | 24635167 | 34 | 56078 | |||
| 2024-02-13 | SC 13G | SCHEDULE 13G | 0001104659-24-021478 | 005-91075 | 24628987 | 34 | 13014 | |||
| 2024-02-05 | 4 | xslF345X05/form4-02062024_020209.xml | 0001415889-24-002757 | 5497 | ||||||
| 2024-02-05 | 4 | xslF345X05/form4-02062024_020236.xml | 0001415889-24-002756 | 4795 | ||||||
| 2024-02-05 | 4 | xslF345X05/form4-02062024_020222.xml | 0001415889-24-002755 | 4808 | ||||||
| 2024-02-05 | 4 | xslF345X05/form4-02062024_020203.xml | 0001415889-24-002754 | 5513 | ||||||
| 2024-02-02 | 4 | xslF345X05/form4-02032024_020214.xml | 0001415889-24-002412 | 8863 | ||||||
| 2024-01-31 | SC 13G | us6047491013_013124.txt | 0001086364-24-006067 | 005-91075 | 24582187 | 34 | 13544 | |||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070108.xml | 0001415889-24-001826 | 8103 | ||||||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070106.xml | 0001415889-24-001825 | 8108 | ||||||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070104.xml | 0001415889-24-001824 | 8057 | ||||||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070108.xml | 0001415889-24-001827 | 8105 | ||||||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070101.xml | 0001415889-24-001823 | 8124 | ||||||
| 2024-01-25 | 4 | xslF345X05/form4-01252024_070102.xml | 0001415889-24-001822 | 8128 | ||||||
| 2024-01-18 | 4 | xslF345X05/form4-01192024_120106.xml | 0001415889-24-001561 | 8095 | ||||||
| 2024-01-18 | 3 | xslF345X02/form3-01192024_120107.xml | 0001415889-24-001560 | 8202 | ||||||
| 2024-01-16 | 8-K | 8-K | 5.02 | 0001193125-24-008569 | 001-38981 | 24535332 | 34 | 145227 | 1 | 1 |
| 2024-01-09 | 4 | xslF345X05/form4-01102024_010106.xml | 0001415889-24-000884 | 4814 | ||||||
| 2024-01-09 | 4 | xslF345X05/form4-01102024_010122.xml | 0001415889-24-000883 | 4796 | ||||||
| 2024-01-09 | 4 | xslF345X05/form4-01102024_010110.xml | 0001415889-24-000882 | 5507 | ||||||
| 2024-01-09 | 4 | xslF345X05/form4-01102024_010133.xml | 0001415889-24-000881 | 5507 | ||||||
| 2024-01-09 | 4 | xslF345X05/form4-01102024_010137.xml | 0001415889-24-000880 | 8845 | ||||||
| 2024-01-08 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-24-003965 | 001-38981 | 24518493 | 34 | 4822996 | 1 | 1 |
| 2023-12-29 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / MIRUM PHARMACEUTICALS, INC. -- SCHEDULE 13D | 0001072613-23-000635 | 005-91075 | 231527597 | 34 | 100711 | |||
| 2023-12-18 | 8-K | 8-K | 8.01 | 0001193125-23-297614 | 001-38981 | 231493749 | 34 | 147334 | 1 | 1 |
| 2023-12-06 | 4 | FORM 4 SUBMISSION | 0001209191-23-057650 | 8562 | ||||||
| 2023-11-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-055436 | 5553 | ||||||
| 2023-11-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-055434 | 4842 | ||||||
| 2023-11-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-055433 | 4860 | ||||||
| 2023-11-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-055180 | 6475 | ||||||
| 2023-11-02 | S-8 | S-8 | 0001193125-23-269483 | 333-275283 | 231373434 | 33 | 78433 | |||
| 2023-11-02 | 424B5 | 424B5 | 0001193125-23-269478 | 333-267357 | 231373388 | 33 | 621166 | |||
| 2023-11-02 | 10-Q | 10-Q | 0000950170-23-058228 | 001-38981 | 231372514 | 34 | 14304213 | 1 | 1 | |
| 2023-11-02 | 8-K | MIRUM PHARMACEUTICALS, INC. 8-K | 2.02,9.01 | 0001157523-23-001631 | 001-38981 | 231372232 | 34 | 378700 | 1 | 1 |
| 2023-11-02 | 8-K/A | 8-K/A | 9.01 | 0001193125-23-269359 | 001-38981 | 231372193 | 34 | 718303 | 1 | 1 |
| 2023-10-17 | 8-K | 8-K | 8.01 | 0001193125-23-257711 | 001-38981 | 231330004 | 34 | 152244 | 1 | 1 |
| 2023-10-13 | S-3ASR | S-3ASR | 0001193125-23-256146 | 333-274973 | 231325505 | 33 | 294041 | |||
| 2023-10-13 | 8-K | 8-K | 8.01,9.01 | 0001193125-23-256103 | 001-38981 | 231325248 | 34 | 759210 | 1 | 1 |
| 2023-09-18 | SC 13G | SCHEDULE 13G | 0000921895-23-002186 | 005-91075 | 231261588 | 34 | 285775 | |||
| 2023-09-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-049614 | 7023 | ||||||
| 2023-09-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-049511 | 15436 | ||||||
| 2023-09-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-004048 | 001-38981 | 231255775 | 33 | 5378 | |||
| 2023-09-13 | 4 | FORM 4 SUBMISSION | 0001209191-23-049292 | 8992 | ||||||
| 2023-09-12 | 4 | FORM 4 SUBMISSION | 0001209191-23-049133 | 10093 | ||||||
| 2023-09-12 | 3 | FORM 3 SUBMISSION | 0001209191-23-049129 | 6035 | ||||||
| 2023-09-11 | 8-K | 8-K | 5.02,9.01 | 0001193125-23-232481 | 001-38981 | 231247952 | 34 | 191947 | 1 | 1 |
| 2023-09-06 | 144 | xsl144X01/primary_doc.xml | 0001972362-23-000779 | 001-38981 | 231240215 | 33 | 4152 | |||
| 2023-09-05 | SC 13D/A | SC 13D/A | 0001193125-23-228444 | 005-91075 | 231235353 | 34 | 544877 | |||
| 2023-09-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-048086 | 6477 | ||||||
| 2023-09-05 | 8-K | 8-K | 2.01,3.02,7.01,9.01 | 0001193125-23-228131 | 001-38981 | 231234227 | 34 | 200058 | 1 | 1 |
| 2023-08-30 | 8-K | 8-K | 5.02,9.01 | 0001193125-23-224944 | 001-38981 | 231225435 | 34 | 311513 | 1 | 1 |
| 2023-08-28 | 4 | FORM 4 SUBMISSION | 0001209191-23-047515 | 4555 | ||||||
| 2023-08-07 | 10-Q | 10-Q | 0000950170-23-038716 | 001-38981 | 231145521 | 34 | 14228368 | 1 | 1 | |
| 2023-08-03 | 8-K | MIRUM PHARMACEUTICALS, INC. 8-K | 2.02,9.01 | 0001157523-23-001254 | 001-38981 | 231139865 | 34 | 321290 | 1 | 1 |
| 2023-07-17 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-23-187712 | 001-38981 | 231090578 | 34 | 2964901 | 1 | 1 |
| 2023-07-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-041344 | 4786 | ||||||
| 2023-07-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-041338 | 4768 | ||||||
| 2023-07-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-041337 | 5480 | ||||||
| 2023-07-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-041333 | 12909 | ||||||
| 2023-07-05 | 4 | FORM 4 SUBMISSION | 0001209191-23-041330 | 5480 | ||||||
| 2023-06-23 | SC 13D/A | NEW ENTERPRISE ASSOCIATES 16, L.P. / MIRUM PHARMACEUTICALS, INC. -- SCHEDULE 13D | 0001072613-23-000370 | 005-91075 | 231037047 | 34 | 384291 | |||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037366 | 12136 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037363 | 19501 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037361 | 14752 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037360 | 14119 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037356 | 11421 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037353 | 12091 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037346 | 11998 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037343 | 11642 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037333 | 6001 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037135 | 5358 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037133 | 8463 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037131 | 8444 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037129 | 8454 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037127 | 8445 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037124 | 8476 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037123 | 8414 | ||||||
| 2023-06-14 | 4 | FORM 4 SUBMISSION | 0001209191-23-037122 | 5373 | ||||||
| 2023-06-13 | 8-K | 8-K | 5.07 | 0001193125-23-166018 | 001-38981 | 231011252 | 34 | 156531 | 1 | 1 |
| 2023-06-09 | 4 | FORM 4 SUBMISSION | 0001209191-23-035831 | 10188 | ||||||
| 2023-06-08 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-001435 | 001-38981 | 231003115 | 33 | 5290 | |||
| 2023-05-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-030964 | 7936 | ||||||
| 2023-05-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-030966 | 7917 | ||||||
| 2023-05-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-030962 | 8624 | ||||||
| 2023-05-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-030951 | 8623 | ||||||
| 2023-05-09 | 3 | FORM 3 SUBMISSION | 0001209191-23-028316 | 20876 | ||||||
| 2023-05-04 | 4 | FORM 4 SUBMISSION | 0001209191-23-027549 | 13265 | ||||||
| 2023-05-04 | 10-Q | 10-Q | 0000950170-23-017879 | 001-38981 | 23888975 | 34 | 11780845 | 1 | 1 | |
| 2023-05-04 | 8-K | MIRUM PHARMACEUTICALS, INC. 8-K | 2.02,9.01 | 0001157523-23-000741 | 001-38981 | 23888522 | 34 | 275762 | 1 | 1 |
| 2023-05-03 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000374 | 001-38981 | 23885556 | 33 | 4640 | |||
| 2023-05-03 | SC 13G/A | e618579_sc13ga-mirum.htm | 0001193805-23-000657 | 005-91075 | 23885136 | 34 | 130158 | |||
| 2023-05-01 | ARS | ARS | 0001140361-23-022060 | 001-38981 | 23873926 | 34 | 1742296 | |||
| 2023-05-01 | DEFA14A | DEFA14A | 0001140361-23-022058 | 001-38981 | 23873900 | 34 | 4002396 | |||
| 2023-05-01 | DEF 14A | DEF14A | 0001140361-23-022054 | 001-38981 | 23873873 | 34 | 2080481 | |||
| 2023-04-17 | 8-K | 8-K | 1.01,1.02,2.03,3.02,9.01 | 0001193125-23-103622 | 001-38981 | 23824174 | 34 | 957428 | 1 | 1 |
| 2023-04-14 | SC 13D/A | SC 13D/A | 0001193125-23-101762 | 005-91075 | 23820428 | 34 | 431283 | |||
| 2023-04-12 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-23-098423 | 001-38981 | 23814597 | 34 | 184404 | 1 | 1 |
| 2023-04-06 | 4 | FORM 4 SUBMISSION | 0001209191-23-023648 | 5350 | ||||||
| 2023-04-06 | 3 | FORM 3 SUBMISSION | 0001209191-23-023645 | 6009 | ||||||
| 2023-04-06 | 8-K | 8-K | 5.02 | 0001193125-23-093126 | 001-38981 | 23804385 | 34 | 152677 | 1 | 1 |
| 2023-03-10 | 8-K | 8-K | 8.01 | 0001193125-23-067794 | 001-38981 | 23724986 | 34 | 154343 | 1 | 1 |
| 2023-03-09 | S-8 | S-8 | 0001193125-23-066124 | 333-270399 | 23719975 | 33 | 89187 | |||
| 2023-03-08 | 10-K | 10-K | 0000950170-23-006715 | 001-38981 | 23716322 | 34 | 15899834 | 1 | 1 | |
| 2023-03-08 | 8-K | MIRUM PHARMACEUTICALS, INC. 8-K | 2.02,9.01 | 0001157523-23-000411 | 001-38981 | 23716116 | 34 | 306369 | 1 | 1 |
| 2023-03-08 | SC 13G/A | us6047491013_030723.txt | 0001306550-23-008791 | 005-91075 | 23715590 | 34 | 12374 | |||
| 2023-02-14 | SC 13G/A | rocksprings-mirm123122a4.htm | 0001172661-23-001259 | 005-91075 | 23627621 | 34 | 109798 | |||
| 2023-02-14 | SC 13G | SC 13G | 0001580642-23-000863 | 005-91075 | 23626527 | 34 | 58493 | |||
| 2023-02-10 | SC 13G/A | e618234_sc13ga-mirum.htm | 0001193805-23-000121 | 005-91075 | 23608909 | 34 | 131453 | |||
| 2023-02-03 | SC 13G | us6047491013_020323.txt | 0001306550-23-007707 | 005-91075 | 23586200 | 34 | 13307 | |||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006312 | 7241 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006305 | 7952 |
One latest value per concept from companyfacts (284 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 65.28M | 2026-10-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 2.30B | 2025-06-30 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| ecd | CoSelectedMeasureAmt | CoSelectedMeasureAmt | USD | 521.31M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 9.61M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 3.49M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | PeerGroupTotalShareholderRtnAmt | PeerGroupTotalShareholderRtnAmt | USD | 124.72 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 29.65M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 10.44M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 495.24 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-23 | 0001759425-26-000027 | ||
| us-gaap | AccountsAndOtherReceivablesNetCurrent | Accounts and Other Receivables, Net, Current | USD | 400,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0000950170-21-004605 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 13.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 156.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | 1.73M | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-15 | 0000950170-24-032289 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 196.19M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | AccruedProfessionalFeesCurrent | Accrued Professional Fees, Current | USD | 23.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AccruedRoyaltiesCurrent | Accrued Royalties, Current | USD | 20.18M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 1.10M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -2.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 1.51B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 33.20M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | AdvertisingExpense | Advertising Expense | USD | 10.90M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 121.36M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AmortizationOfFinancingCostsAndDiscounts | Amortization of Debt Issuance Costs and Discounts | USD | 1.96M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | AmortizationOfIntangibleAssets | Amortization of Intangible Assets | USD | 20.30M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 18.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | AreaOfLand | Area of Land | sqft | 5,600 | 2019-01-31 | 2024 | FY | 10-K | 2025-02-26 | 0001759425-25-000014 | |
| us-gaap | AssetAcquisitionContingentConsiderationLiabilityCurrent | AssetAcquisitionContingentConsiderationLiabilityCurrent | USD | 24.80M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AssetAcquisitionContingentConsiderationLiabilityNoncurrent | AssetAcquisitionContingentConsiderationLiabilityNoncurrent | USD | 44.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | Assets | Assets | USD | 1.03B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 586.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AssetsFairValueDisclosure | Assets, Fair Value Disclosure | USD | 426.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 1.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 428.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value | USD | 149.59M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023519 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year | USD | 140.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value | USD | 267.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | USD | 86.64M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 426.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 130.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesNoncurrent | Debt Securities, Available-for-sale, Noncurrent | USD | 126.77M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedGainLossNet | Available-for-sale Securities, Gross Realized Gain (Loss) | USD | 0 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0000950170-21-004605 |
| us-gaap | AvailableForSaleSecuritiesGrossRealizedLosses | Available-for-sale Securities, Gross Realized Losses | USD | 0 | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-28 | 0001564590-19-033345 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 42,000 | 2020-01-01 | 2020-06-30 | 2021 | Q2 | 10-Q | 2021-08-05 | 0000950170-21-000954 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 243.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CashAndCashEquivalentsFairValueDisclosure | Cash and Cash Equivalents, Fair Value Disclosure | USD | 169.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | 244.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -53.24M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | CommitmentsAndContingencies | Commitments and Contingencies | USD | 0 | 2021-03-31 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001564590-21-024994 | |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 27.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 200.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 65.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 65.21M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 7,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -900.55M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ContractWithCustomerAssetNet | Contract with Customer, Asset, after Allowance for Credit Loss | USD | 0 | 2026-03-31 | 2026 | Q1 | 10-Q | 2026-05-06 | 0001759425-26-000037 | |
| us-gaap | ContractWithCustomerLiability | Contract with Customer, Liability | USD | 5.90M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod | Contract with Customer, Performance Obligation Satisfied in Previous Period | USD | 11.00M | 2025-01-01 | 2025-06-30 | 2025 | Q2 | 10-Q | 2025-08-06 | 0001759425-25-000041 |
| us-gaap | ConversionOfStockAmountIssued1 | Conversion of Stock, Amount Issued | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 |
| us-gaap | ConvertibleDebtFairValueDisclosures | Convertible Debt, Fair Value Disclosures | USD | 782.43M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ConvertibleLongTermNotesPayable | Convertible Notes Payable, Noncurrent | USD | 731.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ConvertibleNotesPayable | Convertible Notes Payable | USD | 731.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | -80,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | CurrentForeignTaxExpenseBenefit | Current Foreign Tax Expense (Benefit) | USD | 1.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | 1.94M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 819,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | DebtConversionConvertedInstrumentAmount1 | Debt Conversion, Converted Instrument, Amount | USD | 600.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | DebtSecuritiesAvailableForSaleAllowanceForCreditLoss | Debt Securities, Available-for-sale, Allowance for Credit Loss | USD | 0 | 2024-09-30 | 2024 | Q3 | 10-Q | 2024-11-12 | 0001759425-24-000038 | |
| us-gaap | DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | DebtSecuritiesAvailableForSaleRealizedGainLoss | Debt Securities, Available-for-sale, Realized Gain (Loss) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | DeferredFederalIncomeTaxExpenseBenefit | Deferred Federal Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | DeferredIncomeTaxExpenseBenefit | Deferred Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 1.63M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredStateAndLocalIncomeTaxExpenseBenefit | Deferred State and Local Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 183.45M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsInventory | Deferred Tax Assets, Inventory | USD | 1.77M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 45.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsOther | Deferred Tax Assets, Other | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 49.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 48.78M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 9.88M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals | USD | 7.07M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 181.82M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DeferredTaxLiabilitiesLeasingArrangements | Deferred Tax Liabilities, Leasing Arrangements | USD | 1.53M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | DepreciationDepletionAndAmortization | Depreciation, Depletion and Amortization | USD | 20.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | DepreciationExpenseOnReclassifiedAssets | Depreciation Expense on Reclassified Assets | USD | 300,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | DerivativeLiabilities | Derivative Liability | USD | 0 | 2023-12-31 | 2024 | FY | 10-K | 2025-02-26 | 0001759425-25-000014 | |
| us-gaap | DerivativeLiabilitiesCurrent | Derivative Liability, Current | USD | 0 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -14.35 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.17 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-05 | 0000950170-22-007812 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -14.35 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | -0.09 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.55 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectAmount | USD | 527,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent | pure | -0.025 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationGiltiPercent | EffectiveIncomeTaxRateReconciliationGiltiPercent | pure | 0.017 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-15 | 0000950170-24-032289 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent | pure | -0.004 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | 0.241 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent | Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent | pure | -0.004 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings | Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent | pure | -0.005 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | -0.03 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Percent | pure | -0.147 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Percent | pure | -0.589 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | USD | -2.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 40.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount | Share-based Payment Arrangement, Amount Capitalized | USD | 700,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | FairValueAssetsLevel1ToLevel2TransfersAmount | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | FairValueAssetsLevel2ToLevel1TransfersAmount | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | FairValueLiabilitiesLevel1ToLevel2TransfersAmount | Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | FairValueLiabilitiesLevel2ToLevel1TransfersAmount | Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount | USD | 0 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3 | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements) | USD | 0 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-15 | 0000950170-24-032289 |
| us-gaap | FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-26 | 0001759425-25-000014 |
| us-gaap | FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs | USD | 1.26M | 2020-12-31 | 2021 | FY | 10-K | 2022-03-09 | 0000950170-22-003229 | |
| us-gaap | FinancialLiabilitiesFairValueDisclosure | Financial Liabilities Fair Value Disclosure | USD | 44.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAccumulatedAmortization | Finite-Lived Intangible Assets, Accumulated Amortization | USD | 80.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive | Finite-Lived Intangible Asset, Expected Amortization, after Year Five | USD | 127.00M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths | Finite-Lived Intangible Asset, Expected Amortization, Year One | USD | 29.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year | USD | 7.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFive | Finite-Lived Intangible Asset, Expected Amortization, Year Five | USD | 26.74M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearFour | Finite-Lived Intangible Asset, Expected Amortization, Year Four | USD | 29.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearThree | Finite-Lived Intangible Asset, Expected Amortization, Year Three | USD | 29.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo | Finite-Lived Intangible Asset, Expected Amortization, Year Two | USD | 29.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsGross | Finite-Lived Intangible Assets, Gross | USD | 356.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | FiniteLivedIntangibleAssetsNet | Finite-Lived Intangible Assets, Net | USD | 275.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ForeignCurrencyTransactionGainLossRealizedAfterTax | ForeignCurrencyTransactionGainLossRealizedAfterTax | USD | 800,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ForeignCurrencyTransactionGainLossUnrealized | Foreign Currency Transaction Gain (Loss), Unrealized | USD | -1.82M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ForeignCurrencyTransactionGainLossUnrealizedAfterTax | ForeignCurrencyTransactionGainLossUnrealizedAfterTax | USD | 1.90M | 2025-01-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-04 | 0001759425-25-000054 |
| us-gaap | GainsLossesOnExtinguishmentOfDebt | Gain (Loss) on Extinguishment of Debt | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 59.22M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-09 | 0000950170-22-003229 |
| us-gaap | HeldToMaturitySecuritiesFairValue | Debt Securities, Held-to-maturity, Fair Value | USD | 149.59M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023519 | |
| us-gaap | ImpairmentOfLongLivedAssetsToBeDisposedOf | Impairment of Long-Lived Assets to be Disposed of | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -24.88M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -895.45M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | 3.45M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxesPaid | Income Taxes Paid | USD | 125,000 | 2023-01-01 | 2023-12-31 | 2023 | FY | 10-K | 2024-03-15 | 0000950170-24-032289 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 3.28M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 2.70M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncomeTaxPaidFederalAfterRefundReceived | IncomeTaxPaidFederalAfterRefundReceived | USD | 53,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 11.78M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -4.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseOther | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount | USD | 83,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | -5.17M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | 641,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationTaxContingencies | Effective Income Tax Rate Reconciliation, Tax Contingency, Amount | USD | 3.16M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncomeTaxReconciliationTaxCredits | Effective Income Tax Rate Reconciliation, Tax Credit, Amount | USD | 12.63M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | 39.69M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncreaseDecreaseInInventories | Increase (Decrease) in Inventories | USD | 2.41M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -1.72M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncreaseDecreaseInOtherOperatingAssets | Increase (Decrease) in Other Operating Assets | USD | 10.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 12.02M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | IntangibleAssetsNetExcludingGoodwill | Intangible Assets, Net (Excluding Goodwill) | USD | 275.65M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InterestExpenseDebt | Interest Expense, Debt | USD | 7.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | InterestExpenseDebtExcludingAmortization | Interest Expense, Debt, Excluding Amortization | USD | 5.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | InterestExpenseInterestBearingLiabilityIncreaseDecrease | InterestExpenseInterestBearingLiabilityIncreaseDecrease | USD | 0 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-15 | 0000950170-24-032289 |
| us-gaap | InterestExpenseNonoperating | InterestExpenseNonoperating | USD | 7.84M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 7.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | InterestPayableCurrent | Interest Payable, Current | USD | 984,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InventoryFinishedGoods | Inventory, Finished Goods, Gross | USD | 4.04M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InventoryNet | Inventory, Net | USD | 25.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InventoryRawMaterialsAndSupplies | Inventory, Raw Materials and Supplies, Gross | USD | 2.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InventoryWorkInProcess | Inventory, Work in Process, Gross | USD | 18.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 11.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | Investments | Investments | USD | 0 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 | |
| us-gaap | InvestmentsAndCash | Investments and Cash | USD | 500.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseDiscountRate | Lessee, Operating Lease, Discount Rate | pure | 0.08 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-041030 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 14.56M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 21,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 3.42M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 351,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 2.71M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 2.92M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 2.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 823,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 2.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | Liabilities | Liabilities | USD | 1.08B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 1.03B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 283.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LongTermInvestments | Long-term Investments | USD | 126.77M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LossContingencyNewClaimsFiledNumber | Loss Contingency, New Claims Filed, Number | claim | 4 | 2025-12-19 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | LossContingencyPendingClaimsNumber | Loss Contingency, Pending Claims, Number | claim | 4 | 2026-04-16 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 427.17M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | -200.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -277.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -898.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersBasic | Net Income (Loss) Available to Common Stockholders, Basic | USD | -898.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NetIncomeLossAvailableToCommonStockholdersDiluted | Net Income (Loss) Available to Common Stockholders, Diluted | USD | -898.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 1.41B | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -891.75M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 2.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 12.31M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 2.60M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 9.72M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 2.40M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 11.36M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OperatingLeaseRightOfUseAssetAmortizationExpense | Operating Lease, Right-of-Use Asset, Amortization Expense | USD | 144,000 | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-04 | 0000950170-23-017879 |
| us-gaap | OperatingLeaseVariableLeaseIncome | Operating Lease, Variable Lease Income | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.075 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OtherAccruedLiabilitiesNoncurrent | Other Accrued Liabilities, Noncurrent | USD | 973,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 21.23M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent | USD | -1.85M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | USD | -560,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent | Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent | USD | -1.38M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 12.10M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | 929,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -7.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale | USD | 0 | 2023-01-01 | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-02 | 0000950170-23-058228 |
| us-gaap | PaymentOfFinancingAndStockIssuanceCosts | Payment of Financing and Stock Issuance Costs | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | PaymentsForProceedsFromInvestments | Payments for (Proceeds from) Investments | USD | 65.00M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-08 | 0000950170-23-006715 |
| us-gaap | PaymentsForTenantImprovements | Payments for Tenant Improvements | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 |
| us-gaap | PaymentsOfDebtIssuanceCosts | Payments of Debt Issuance Costs | USD | 17.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | PaymentsToAcquireBusinessesGross | Payments to Acquire Businesses, Gross | USD | 2.60M | 2022-05-01 | 2022-05-31 | 2023 | Q1 | 10-Q | 2023-05-04 | 0000950170-23-017879 |
| us-gaap | PaymentsToAcquireBusinessesNetOfCashAcquired | Payments to Acquire Businesses, Net of Cash Acquired | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | PaymentsToAcquireInProcessResearchAndDevelopment | Payments to Acquire in Process Research and Development | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | PaymentsToAcquireIntangibleAssets | Payments to Acquire Intangible Assets | USD | 35.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 249.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 1.99M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | PreferredStockLiquidationPreferenceValue | Preferred Stock, Liquidation Preference, Value | USD | 0 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-08 | 0000950170-23-006715 | |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 10.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 31.11M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ProceedsFromConvertibleDebt | Proceeds from Convertible Debt | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | ProceedsFromDebtNetOfIssuanceCosts | Proceeds from Debt, Net of Issuance Costs | USD | 672.05M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-26 | 0001759425-25-000014 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockAndPreferenceStock | Proceeds from Issuance of Preferred Stock and Preference Stock | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 259.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock | Proceeds from Issuance of Redeemable Convertible Preferred Stock | USD | 60.00M | 2019-04-12 | 2019 | Q2 | 10-Q | 2019-08-28 | 0001564590-19-033345 | |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised | USD | 31.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | USD | 85.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ProceedsFromRelatedPartyDebt | Proceeds from Related Party Debt | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -898.15M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 3.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ProvisionForDoubtfulAccounts | Accounts Receivable, Credit Loss Expense (Reversal) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ReclassificationsOfTemporaryToPermanentEquity | Reclassifications of Temporary to Permanent Equity | USD | 6.99M | 2019-01-01 | 2019-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 |
| us-gaap | RepaymentsOfConvertibleDebt | Repayments of Convertible Debt | USD | 536.08M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 28.61M | 2019-01-01 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-041030 |
| us-gaap | ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | Research and Development Expense (Excluding Acquired in Process Cost) | USD | 296.37M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ResearchAndDevelopmentInProcess | Research and Development in Process | USD | 0 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-12 | 0001564590-20-010471 |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 1.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | RestrictedCashEquivalents | Restricted Cash Equivalents | USD | 1.74M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -1.57B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 521.85M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | Revenues | Revenues | USD | 19.14M | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-09 | 0000950170-22-003229 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 4.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | SellingGeneralAndAdministrativeExpense | Selling, General and Administrative Expense | USD | 266.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 100.08M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost | Share-based Goods and Nonemployee Services Transaction, Modification of Terms, Incremental Compensation Cost | USD | 600,000 | 2021-01-01 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-15 | 0000950170-21-004605 |
| us-gaap | ShortTermInvestments | Short-term Investments | USD | 130.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | ShortTermLeaseCommitmentAmount | Short-term Lease Commitment, Amount | USD | 400,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-06 | 0001564590-19-041030 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -54.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.125 | 2019-07-01 | 2019-07-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 |
| us-gaap | StockIssued1 | Stock Issued | USD | 329.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities | Stock Issued During Period, Shares, Conversion of Convertible Securities | shares | 31 | 2026-04-01 | 2026-06-30 | 2026 | Q2 | 10-Q | 2026-08-05 | 0001759425-26-000045 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 415.27M | 2026-01-01 | 2026-03-31 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 3,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 10.13M | 2026-01-01 | 2026-03-31 | 2026 | Q2 | 10-Q | 2026-08-05 | 0001759425-26-000045 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 329.09M | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 345,000 | 2021-07-01 | 2021-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023519 |
| us-gaap | TenantImprovements | Tenant Improvements | USD | 400,000 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-28 | 0001564590-19-033345 | |
| us-gaap | TreasuryStockCommonShares | Treasury Stock, Common, Shares | shares | 456,445 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-28 | 0001564590-19-033345 | |
| us-gaap | UndistributedEarningsOfForeignSubsidiaries | Undistributed Earnings of Foreign Subsidiaries | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 17.12M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions | USD | 110,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued | Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-09 | 0000950170-22-003229 | |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 4.27M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 337,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | USD | 3.60M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-09 | 0001564590-21-011756 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 14.40M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-25 | 0001759425-26-000013 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 62.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 31.30M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-05 | 0000950170-22-007812 |
| us-gaap | WeightedAverageNumberOfSharesContingentlyIssuable | Weighted Average Number of Shares, Contingently Issuable | shares | 493,185 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 62.61M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-03 | 0001759425-26-000062 |